The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
Aim: to learn the role of docetaxel in non-castrate resistant prostate cancer patient. Methods: literature search was conducted to find relevant study comparing the combination of docetaxel and androgen deprivation therapy (ADT) to ADT alone in non-castrate resistant prostate cancer using PubMed, Co...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2017-05-01
|
| Series: | Acta Medica Indonesiana |
| Subjects: | |
| Online Access: | https://actamedindones.org/index.php/ijim/article/view/244 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850059550063853568 |
|---|---|
| author | Fakhri Rahman Harrina Erlianti Rahardjo Stefanus Cahyo Ariwicaksono Hafizar Hafizar Muhammad Gozali Arif Sembiring Rendy Andika Richman Patandung Septiani Hidianingsih Stevano Lucianto Hotasi |
| author_facet | Fakhri Rahman Harrina Erlianti Rahardjo Stefanus Cahyo Ariwicaksono Hafizar Hafizar Muhammad Gozali Arif Sembiring Rendy Andika Richman Patandung Septiani Hidianingsih Stevano Lucianto Hotasi |
| author_sort | Fakhri Rahman |
| collection | DOAJ |
| description | Aim: to learn the role of docetaxel in non-castrate resistant prostate cancer patient. Methods: literature search was conducted to find relevant study comparing the combination of docetaxel and androgen deprivation therapy (ADT) to ADT alone in non-castrate resistant prostate cancer using PubMed, Cohrane Library, Proquest, EBSCO, and Scopus database. Quality assessment of studies was done using Bond University Rapid Critical Appraisal of a Systematic Review. Results: we found 494 studies from literature search, but only two studies were included in final selection. Based on validity assessment, we chose one study to be discussed further. This study showed that combination of docetaxel and ADT is better than ADT alone in regards of overall survival (HR 0.64; 95% CI 0.55, 0.75; p<0.0001; NNT=3), biochemical progression free survival (HR 0.63; 95% CI 0.57, 0.69; p<0.0001; NNT=2) and clinical progression free survival (HR 0.73; 95% CI 0.64, 0.84; p<0.0001; NNT=2). Benefit of docetaxel and ADT combination was especially seen in high volume disease (HR 0.67; 95% CI 0.54, 0.83; p=0.0003; NNT=3). Conclusion: addition of docetaxel into ADT has beneficial effects in terms of overall survival and progression free survival in patients with non-castrate resistant metastatic prostate cancer. |
| format | Article |
| id | doaj-art-cd88f460bf7a4161819d77cc9018e648 |
| institution | DOAJ |
| issn | 0125-9326 2338-2732 |
| language | English |
| publishDate | 2017-05-01 |
| publisher | Interna Publishing |
| record_format | Article |
| series | Acta Medica Indonesiana |
| spelling | doaj-art-cd88f460bf7a4161819d77cc9018e6482025-08-20T02:50:52ZengInterna PublishingActa Medica Indonesiana0125-93262338-27322017-05-01491The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case ReportFakhri Rahman0Harrina Erlianti Rahardjo1Stefanus Cahyo Ariwicaksono2Hafizar Hafizar3Muhammad Gozali Arif Sembiring4Rendy Andika5Richman Patandung6Septiani Hidianingsih7Stevano Lucianto Hotasi8Department of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas IndonesiaDepartment of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas IndonesiaDepartment of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas IndonesiaDepartment of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas IndonesiaDepartment of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas IndonesiaDepartment of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas IndonesiaDepartment of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas IndonesiaDepartment of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas IndonesiaDepartment of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital Faculty of Medicine, Universitas IndonesiaAim: to learn the role of docetaxel in non-castrate resistant prostate cancer patient. Methods: literature search was conducted to find relevant study comparing the combination of docetaxel and androgen deprivation therapy (ADT) to ADT alone in non-castrate resistant prostate cancer using PubMed, Cohrane Library, Proquest, EBSCO, and Scopus database. Quality assessment of studies was done using Bond University Rapid Critical Appraisal of a Systematic Review. Results: we found 494 studies from literature search, but only two studies were included in final selection. Based on validity assessment, we chose one study to be discussed further. This study showed that combination of docetaxel and ADT is better than ADT alone in regards of overall survival (HR 0.64; 95% CI 0.55, 0.75; p<0.0001; NNT=3), biochemical progression free survival (HR 0.63; 95% CI 0.57, 0.69; p<0.0001; NNT=2) and clinical progression free survival (HR 0.73; 95% CI 0.64, 0.84; p<0.0001; NNT=2). Benefit of docetaxel and ADT combination was especially seen in high volume disease (HR 0.67; 95% CI 0.54, 0.83; p=0.0003; NNT=3). Conclusion: addition of docetaxel into ADT has beneficial effects in terms of overall survival and progression free survival in patients with non-castrate resistant metastatic prostate cancer.https://actamedindones.org/index.php/ijim/article/view/244Docetaxelandrogen deprivation therapyevidence-based case reportmetastatic prostate canceroverall survival |
| spellingShingle | Fakhri Rahman Harrina Erlianti Rahardjo Stefanus Cahyo Ariwicaksono Hafizar Hafizar Muhammad Gozali Arif Sembiring Rendy Andika Richman Patandung Septiani Hidianingsih Stevano Lucianto Hotasi The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report Acta Medica Indonesiana Docetaxel androgen deprivation therapy evidence-based case report metastatic prostate cancer overall survival |
| title | The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report |
| title_full | The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report |
| title_fullStr | The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report |
| title_full_unstemmed | The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report |
| title_short | The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report |
| title_sort | role of docetaxel in non castrate resistant metastatic prostate cancer an evidence based case report |
| topic | Docetaxel androgen deprivation therapy evidence-based case report metastatic prostate cancer overall survival |
| url | https://actamedindones.org/index.php/ijim/article/view/244 |
| work_keys_str_mv | AT fakhrirahman theroleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport AT harrinaerliantirahardjo theroleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport AT stefanuscahyoariwicaksono theroleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport AT hafizarhafizar theroleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport AT muhammadgozaliarifsembiring theroleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport AT rendyandika theroleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport AT richmanpatandung theroleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport AT septianihidianingsih theroleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport AT stevanoluciantohotasi theroleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport AT fakhrirahman roleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport AT harrinaerliantirahardjo roleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport AT stefanuscahyoariwicaksono roleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport AT hafizarhafizar roleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport AT muhammadgozaliarifsembiring roleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport AT rendyandika roleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport AT richmanpatandung roleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport AT septianihidianingsih roleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport AT stevanoluciantohotasi roleofdocetaxelinnoncastrateresistantmetastaticprostatecanceranevidencebasedcasereport |